drugset / Trial / NCT05636904

Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men

NCT05636904

Phase 1/2 Completed 120 enrolled Dermaliq Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this study is to measure the safety, tolerability, and the hair growth response to topical DLQ01 solutions in comparison to the vehicle and a comparator solution in 120 males with Androgenetic Alopecia.

Timeline

Start
2022-12-05
Primary completion
2024-03-28
Completion
2024-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject DLQ01 Unknown Topical
Comparator Minoxidil Small molecule 5 % Topical

Indications